



**THERMOGENESIS CORP. NAMES CELL THERAPY DEVICE SALES EXPERT
DANIEL A. SEGAL AS VICE PRESIDENT OF SALES & MARKETING**

RANCHO CORDOVA, CA. (February 15, 2007) – ThermoGenesis Corp. (Nasdaq: KOOL), a leader in developing and marketing enabling technologies for cord blood stem cell therapy and surgical wound care, announced today that it appointed Daniel A. Segal as Vice President of Sales and Marketing in its Cell Therapy business, effective February 19, 2007. Mr. Segal returns to the Company from GE Healthcare (GEHC), the distributor for ThermoGenesis' AutoXpress™ and BioArchive® Systems, and brings over twenty years of domestic and international medical technology sales and marketing experience in the specialty surgical, blood banking and stem cell processing markets. Mr. Segal will report directly to Philip H. Coelho, ThermoGenesis' Chairman and Chief Executive Officer.

“We believe that Dan will make an immediate contribution to our current leadership position in the cell processing industry as the U.S. government continues to release funds to promote the growth of a national cord blood stem cell banking system and the FDA moves to regulate both the cell therapy products and the devices that enable their manufacture,” said Mr. Coelho. “I am confident that Dan’s skill set and proven expertise in the field will help accelerate our transformation into a fully commercial organization.”

During his time with GEHC, Mr. Segal helped establish the Cell Technologies Group. While serving as Business Development Manager of GEHC’s Cell Technologies group’s North American region, he played a fundamental role in overseeing the multimillion dollar agreement between GEHC and Cord Blood Registry (CBR), the world’s largest private cord blood bank.

Mr. Segal commented, “I am eager to return to the Company that first sparked my interest in the life saving potential of cell therapies and the importance of the Company’s stem cell banking technologies.”

Prior to GEHC, Mr. Segal worked with ThermoGenesis for nearly half of his two decades in the industry during which time he honed his expertise in the stem cell processing and blood banking markets while he helped the Company achieve many milestones. Between 1997 and 2004, Mr. Segal ascended the ranks at ThermoGenesis by leading the Sales & Marketing group and orchestrating sales of the BioArchive Platform products.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

- **The BioArchive System**, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant. GE Healthcare is the non-exclusive global distribution partner for the BioArchive System.

- **The AutoXpress System (AXP™)** is a newly developed proprietary and patented semi-automated device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood. GE Healthcare is the exclusive global distribution partner for the AXP AutoXpress System.
- **The CryoSeal FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. Enrollment in a 150-patient U.S. pivotal clinical trial has been completed and a PMA is being reviewed by the FDA. The CryoSeal FS System has received the CE-Mark. From a marketing perspective, the CE Mark is the European equivalent to an FDA approval, in that it allows sales of the product throughout the European community.
- **The Thrombin Processing Device™ (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2007, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2007. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.

Web site: <http://www.ThermoGenesis.com>

Contact: Fern Lazar of Lazar Partners

+1-212-867-1762